Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416324 · ClinicalTrials.gov registry record · Phase 1
First Time in Human Study Using GSK2330672
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01416324: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT01416324 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01416324, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.
Primary Outcome
frequency and absolute value change in heart rate, blood pressure, respiration rate relative to placebo
Interventions
- DRUG placebo
- DRUG 0.1 mg GSK2330672
- DRUG 0.3 mg GSK2330672
- DRUG 1 mg GSK2330672
- DRUG 3 mg GSK2330672
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-06-15 |
| Est. Completion | 2011-09-09 |
| Phase | Phase 1 |
What the finished NCT01416324 record still lists
NCT01416324 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01416324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01416324 about?
NCT01416324 is a clinical study titled "First Time in Human Study Using GSK2330672". The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.
What is the current status of trial NCT01416324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2011-06-15. Estimated completion is 2011-09-09.
What interventions are being tested in trial NCT01416324?
The interventions under investigation include: placebo (DRUG), 0.1 mg GSK2330672 (DRUG), 0.3 mg GSK2330672 (DRUG), 1 mg GSK2330672 (DRUG), 3 mg GSK2330672 (DRUG).
Who is sponsoring clinical trial NCT01416324?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01416324's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI